Ovarian Cancer | Specialty

Tumor Gene Methylation May Predict Ovarian Cancer Response to Rucaparib

March 13th 2017

Hypermethylation of 2 wild-type tumor-associated genes increased ovarian cancer responsiveness to the PARP inhibitor rucaparib (Rubraca).

Dr. Barber on Surgical Readmission and Survival in Ovarian Cancer

March 13th 2017

Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses surgical readmission and survival in patients with ovarian cancer.

Dr. Swisher on Next Steps of Treatment for Ovarian Cancer

March 13th 2017

Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses next steps regarding treatments for patients with ovarian cancer.

New Insights Into Rucaparib Activity in Ovarian Cancer

March 13th 2017

The PARP inhibitor rucaparib slowed progression of relapsed BRCA-mutant ovarian cancer regardless of whether the mutations were somatic or germline, a new analysis of a phase II trial showed.

Dr. Markman on 2017 Goals for the Field of Ovarian Cancer

March 2nd 2017

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses what he would like to see accomplished in the field of ovarian cancer over the next year.

PARP Inhibitors Are Changing Paradigm in Recurrent Ovarian Cancer

March 2nd 2017

A panel of gynecologic oncology specialists discusses novel agents for the second, third, fourth, and even fifth lines of therapy and the growing importance of molecular signature, histology, and time to recurrence in treatment decisions.

Antibody-Drug Conjugate Under Study in Platinum-Resistant Ovarian Cancer

February 28th 2017

A novel targeted therapy, mirvetuximab soravtansine (IMGN853), is being investigated as a single-agent treatment for patients with advanced, platinum-resistant epithelial ovarian cancer with medium and high expression levels of folate receptor-alpha in an effort to provide an effective option for a population facing a difficult prognosis.

Expert Discusses Biomarkers for PARP Inhibitors in Ovarian Cancer

February 20th 2017

Dr. Elizabeth Swisher discusses biomarkers for PARP inhibitors and the evolving role of these agents in ovarian cancer.

Mirvetuximab Soravtansine Active in Platinum-Resistant Ovarian Cancer

February 17th 2017

Results of a phase I expansion study demonstrated a manageable safety profile and clinical activity with mirvetuximab soravtansine in the treatment of patients with platinum-resistant ovarian cancer.

Defects in EMSY Gene Spur Ovarian Cancer Growth

February 14th 2017

Douglas A. Levine, MD, discussed the relationship between EMSY and BRCA, the potential to target EMSY amplified tumors with PARP inhibitors, and the future of ovarian cancer treatment.

Dr. Levine on Challenges in Ovarian Cancer

February 14th 2017

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses some of the ongoing challenges researchers need to tackle in the field of ovarian cancer.

Dr. Mirza on Niraparib Efficacy Across Ovarian Cancer Subgroups

February 7th 2017

Mansoor Raza Mirza, MD, chief oncologist at Rigshospitalet, Copenhagen, Denmark, discusses the efficacy of niraparib as a treatment of patients with ovarian cancer.

Dr. Levine on Combos With PARP Inhibitors in Ovarian Cancer

February 4th 2017

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses what potential PARP inhibitors could have with chemotherapy regimens as a treatment for patients with ovarian cancer.

Dr. Muggia on the GOG 252 Trial in Ovarian Cancer

February 2nd 2017

Franco M. Muggia, MD, PhD, professor, Department of Medicine, NYU Langone Medical Center, discusses the GOG 252 trial, which looked at the use of intravenous versus intraperitoneal chemotherapy in the treatment of patients with ovarian cancer.

Laparoscopy Plays Predictive Role for Primary Surgery Outcomes in Ovarian Cancer

January 28th 2017

Diagnostic laparoscopy reduced the number of futile laparotomies in patients with suspected advanced-stage ovarian cancer, according to the results of a recent study.

Study Explores Correlations Among Irregular Menstrual Cycles, PCOS, and Ovarian Cancer Risk

January 27th 2017

Long or irregular menstrual cycles may be a marker of an increased risk for developing certain subtypes of ovarian cancer, according to the results of a recent study.

Expert Discusses Uncertainty Over Ideal IP Chemo Approach in Ovarian Cancer

January 23rd 2017

Franco M. Muggia, MD, discusses the results of the Gynecologic Oncology Group (GOG) 252 trial and what the findings mean regarding intraperitoneal therapy for patients with ovarian cancer.

Future Directions for Treating Advanced Ovarian Cancers

January 20th 2017

Ongoing PARP Inhibitor Research in Ovarian Cancer

January 20th 2017

Differences Among PARP Inhibitors in Ovarian Cancer

January 20th 2017